VIEWS: 2 PAGES: 4 POSTED ON: 7/17/2012
The MRSA Partnering 2007-2012 report provides understanding and access to the MRSA partnering deals and agreements entered into by the worlds leading healthcare companies.
MRSA Partnering 2007-2012 Published : July 2012 No. of Pages : 100 Price:US$995 The MRSA Partnering 2007-2012 report provides understanding and access to the MRSA partnering deals and agreements entered into by the worlds leading healthcare companies. Top MRSA deals by value Deals listed by company A-Z, industry sector, stage of development, technology type The MRSA Partnering 2007-2012 provides understanding and access to the MRSA partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of MRSA partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors MRSA technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. This data driven report contains over 50 links to online copies of actual MRSA deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. Report scope MRSA Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to MRSA trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in MRSA dealmaking in the biopharma industry since 2007 Access to summary headline, upfront, milestone and royalty data The leading MRSA deals by value since 2007 In MRSA Partnering 2007-2012, the available deals are listed by: Headline value Upfront payment value Royalty rate value Company A-Z Industry sector Stage of development at signing Deal component type Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. MRSA Partnering 2007-2012 provides the reader with the following key benefits: In-depth understanding of MRSA deal trends since 2007 Access to summary headline, upfront, milestone and royalty data Comprehensive access to over 50 actual MRSA deals entered into by the world’s biopharma companies since 2007 Insight into key deal terms included in contracts, where disclosed Understand the key deal terms companies have agreed in deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies MRSA Partnering 2007-2012 Table Of contents Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in MRSA partnering 2.1. Introduction 2.2. MRSA partnering over the years 2.3. Bigpharma MRSA dealmaking activity 2.4. MRSA partnering by deal type 2.5. MRSA partnering industry sector 2.6. MRSA partnering by stage of development 2.7. MRSA partnering by technology type 2.8. Disclosed financial deal terms for MRSA partnering 2.8.1 MRSA headline values 2.8.2 MRSA upfront payments 2.8.3 MRSA milestone payments 2.8.4 MRSA royalty rates Chapter 3 – Leading MRSA deals 3.1. Introduction 3.2. Top MRSA deals by value 3.3. Top MRSA deals involving bigpharma Chapter 4 – Dealmaking directory 4.1. Introduction 4.2. Company A-Z 4.3. By deal type Asset purchase Bigpharma outlicensing Co-development Collaborative R&D Co-market Contract service Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Option Promotion Research Settlement Spin out Sub-license Supply Termination 4.4. By industry sector Academic Bigpharma Biotech Drug delivery Medical device Diagnostic Generic pharma Government Non-profit Pharmaceutical Research tools Services Specialty pharma 4.5. By stage of development Discovery Pre-clinical Phase I Phase II Phase III Registration Marketed 4.6. By technology type Analysis Animal models Assays Bioinformatics Biological compounds Biomarkers Biomaterials Cell culture Cell therapy Clinical testing Diagnostic - companion Devices Diagnostics Discovery tools DNA probes Drug delivery Enabling technology Epigenetics Equipment Facilities Gene therapy Genomics Imaging Industrial chemicals In vitro models Monoclonal antibodies Nanotechnology Oligonucleotide Peptides Personalised medicine Processes Proteomics Radio/Chemo-therapy Recombinant DNA Research services Research supplies RNA therapeutics Screening Small molecules Stem cells Vaccines Chapter 5 – Partnering resource center 5.1. Online partnering 5.2. Partnering events 5.3. Further reading on dealmaking Appendices Appendix 1 – Deal type definitions About Wildwood Ventures Current Partnering Current Agreements Recent titles from CurrentPartnering Order Form – Reports List of Figures
Pages to are hidden for
"MRSA Partnering 2007-2012"Please download to view full document